CRA-028129

DB05951ExperimentalSmall molecule

CRA-028129 is cathepsin S inhibitor which is under investigation for the treatment of psoriasis.

Primary indication
Investigated for use/treatment in psoriasis and psoriatic disorders.Curator reviewed
Code names
CRA-028129

Resolves to

Targets
P25774CTSS

What you can answer from here — as of April 02, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above

Which drugs share a target with CRA-028129, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In